Fiona M. Campbell

Fiona M. Campbell

Auto-generated profile, based on publicly available information

Fiona M. Campbell

Department of Paediatric Diabetes, Leeds Children’s Hospital, Leeds, U.K.

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
JLJ. Lawton
J. Lawton
MBM. Blackburn
M. Blackburn
JAJ. Allen
J. Allen
FCF. Campbell
F. Campbell
DED. Elleri
D. Elleri
RHR. Hovorka
R. Hovorka
Continuous glucose monitoring (CGM) enables users to view real-time interstitial glucose readings and provides information on the direction and rate of change of blood glucose levels. Users can also access historical data to inform treatment decisions. While the clinical and psychological benefits of CGM are well established, little is known about how individuals use CGM to inform diabetes self-management. We explored participants’ experiences of using CGM in order to provide recommendations for supporting individuals to make optimal use of this technology. In-depth interviews (n = 24) with adults, adolescents and parents who had used CGM for ≥4 weeks; data were analysed thematically. Participants found CGM an empowering tool because they could access blood glucose data effortlessly, and trend arrows enabled them to see whether blood glucose was rising or dropping and at what speed. This predicative information aided short-term lifestyle planning and enabled individuals to take action to prevent hypoglycaemia and hyperglycaemia. Having easy access to blood glucose data on a continuous basis also allowed participants to develop a better understanding of how insulin, activity and food impacted on blood glucose. This understanding was described as motivating individuals to make dietary changes and break cycles of over-treating hypoglycaemia and hyperglycaemia. Participants also described how historical CGM data provided a more nuanced picture of blood glucose control than was possible with blood glucose self-monitoring and, hence, better information to inform changes to background insulin doses and mealtime ratios. However, while participants expressed confidence making immediate adjustments to insulin and lifestyle to address impending hypoglycaemia and hypoglycaemia, most described needing and expecting health professionals to interpret historical CGM data and determine changes to background insulin doses and mealtime ratios. While alarms could reinforce a sense of hypoglycaemic safety, some individuals expressed ambivalent views, especially those who perceived alarms as signalling personal failure to achieve optimal glycaemic control. CGM can be an empowering and motivational tool which enables participants to fine-tune and optimize their blood glucose control. However, individuals may benefit from psycho-social education, training and/or technological support to make optimal use of CGM data and use alarms appropriately.

28 July 2018 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
FCFiona M. Campbell
Fiona M. Campbell
NMNuala P. Murphy
Nuala P. Murphy
CSCaroline Stewart
Caroline Stewart
TBTorben Biester
Torben Biester
OKOlga Kordonouri
Olga Kordonouri
Background and objective Outcomes of using flash glucose monitoring have been reported in adults. This trial evaluated use in children and teenagers with type 1 diabetes. Methods Prospective, single arm, non‐inferiority multi‐center study to demonstrate equivalence of time in range (TIR [70‐180mg/dL]) by comparing 14‐day masked sensor wear (baseline) with self‐monitored blood glucose (SMBG) testing to the final 14‐days of 8‐week open‐label system use for diabetes self‐management including insulin dosing. Results 76 children and teenagers (46.1% male; age 10.3±4.0 years, type 1 diabetes duration 5.4±3.7 years; mean±SD) from 10 sites participated. TIR improved significantly by 0.9±2.8 hrs/day (p=0.005) versus SMBG baseline. Time in hyperglycemia (>180 mg/dL) reduced by ‐1.2±3.3 hours/day (p=0.004). HbA1c reduced by ‐0.4% (4.4mmol/mol), from 7.9±1.0% (62.9±11.2mmol/mol) baseline to 7.5±0.9% (58.5±9.8mmol/mol) study end, (p<0.0001) with reductions across all age‐subgroups (4‐6, 7‐12, and 13‐17 years). Time in hypoglycemia (<70 mg/dL) was unaffected. Throughout the treatment phase system utilization was 91±9%; sensor scanning was 12.9±5.7/ day with SMBG dropping to 1.6±1.9 from 7.7±2.5/day. Diabetes Treatment Satisfaction Questionnaire ‘Total Treatment Satisfaction’ score improved for parents (p<0.0001) and teenagers (p<0.0001). No adverse events (n=121) were associated with sensor accuracy, 42 participants experienced sensor insertion signs and symptoms. Three participants experienced 3 mild device‐related (sensor wear) symptoms, resolving quickly (without treatment [n=2], non‐prescription antihistamines [n=1]). Conclusions Children with diabetes improved glycemic control safely and effectively with short term flash glucose monitoring use compared within arm, to use of SMBG.

28 January 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MTMartin Tauschmann
Martin Tauschmann
JAJanet M. Allen
Janet M. Allen
KNKatrin Nagl
Katrin Nagl
MFMaria Fritsch
Maria Fritsch
JYJames Yong
James Yong
RHRoman Hovorka
Roman Hovorka
OBJECTIVE We aimed to assess the feasibility and safety of hybrid closed loop insulin delivery in children with type 1 diabetes aged 1–7 years as well as evaluate the role of diluted insulin on glucose control. RESEARCH DESIGN AND METHODS In an open-label, multicenter, multinational, randomized crossover study, 24 children with type 1 diabetes on insulin pump therapy (median age 5 years [interquartile range 3–6] and mean ± SD HbA1c 7.4 ± 0.7% [57 ± 8 mmol/mol] total insulin 13.2 ± 4.8 units/day) underwent two 21-day periods of unrestricted living and we compared hybrid closed loop with diluted insulin (U20) and hybrid closed loop with standard strength insulin (U100) in random order. During both interventions, the Cambridge model predictive control algorithm was used. RESULTS The proportion of time that sensor glucose was in the target range between 3.9 and 10 mmol/L (primary end point) was not different between interventions (mean ± SD 72 ± 8% vs. 70 ± 7% for closed loop with diluted insulin vs. closed loop with standard insulin, respectively; P = 0.16). There was no difference in mean glucose levels (8.0 ± 0.8 vs. 8.2 ± 0.6 mmol/L; P = 0.14), glucose variability (SD of sensor glucose 3.1 ± 0.5 vs. 3.2 ± 0.4 mmol/L; P = 0.16), or the proportion of time spent with sensor glucose <3.9 mmol/L (4.5 ± 1.7% vs. 4.7 ± 1.4%; P = 0.47) or 0.99). Total daily insulin delivery did not differ (17.3 ± 5.6 vs. 18.9 ± 6.9 units/day; P = 0.07). No closed loop–related severe hypoglycemia or ketoacidosis occurred. CONCLUSIONS Unrestricted home use of day and night closed loop in very young children with type 1 diabetes is feasible and safe. The use of diluted insulin during closed loop does not provide additional benefits compared with standard strength insulin.

4 December 2022 in Diabetic Medicine
Verified
Journal Article
Closed access
Sze May NgSze May Ng
Sze May Ng
NWNeil P. Wright
Neil P. Wright
DYDiana Yardley
Diana Yardley
FCFiona Campbell
Fiona Campbell
TRTabitha Randell
Tabitha Randell
PHPeter Hindmarsh
Peter Hindmarsh

24 April 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Sze May NgSze May Ng
Sze May Ng
NWNeil P. Wright
Neil P. Wright
DYDiana Yardley
Diana Yardley
FCFiona Campbell
Fiona Campbell
TRTabitha Randell
Tabitha Randell
PHPeter Hindmarsh
Peter Hindmarsh
Hybrid closed-loop (HCL) systems seamlessly interface continuous glucose monitoring (CGM) with insulin pumps, employing specialised algorithms and user-initiated automated insulin delivery. This study aimed to assess the efficacy of HCLs at 12 months post-initiation on glycated haemoglobin (HbA1c), time-in-range (TIR), hypoglycaemia frequency, and quality of life measures among children and young people (CYP) with type 1 diabetes mellitus (T1DM) and their caregivers in a real-world setting. Conducted between August 1, 2021, and December 10, 2022, the prospective recruitment took place in eight paediatric diabetes centres across England under the National Health Service England’s (NHSE) HCL pilot real-world study. A cohort of 251 CYP (58% males, mean age 12.3 years) with T1DM participated (89% white, 3% Asian, 4% black, 3% mixed ethnicity, and 1% other). The study utilised three HCL systems: (1) Tandem Control-IQ AP system, which uses the Tandem t:slim X2 insulin pump (Tandem Diabetes Care, San Diego, CA, USA) with the Dexcom G6® CGM (Dexcom, San Diego, CA, USA) sensor; (2) Medtronic MiniMed™ 780G with the Guardian 4 sensor (Medtronic, Northridge, CA, USA); and (3) the CamAPS FX (CamDiab, Cambridge, UK) with the Ypsomed insulin pump (Ypsomed Ltd, Escrick, UK) and Dexcom G6® CGM.All systems were fully funded by the NHS. Results demonstrated significant improvements in HbA1c (average reduction at 12 months 7 mmol/mol; P < 0.001), time-in-range (TIR) (average increase 13.4%; P < 0.001), hypoglycaemia frequency (50% reduction), hypoglycaemia fear, and quality of sleep (P < 0.001) among CYP over a 12-month period of HCL usage. Additionally, parents and carers experienced improvements in hypoglycaemia fear and quality of sleep after 6 and 12 months of use. In addition to the improvements in glycaemic management, these findings underscore the positive impact of HCL systems on both the well-being of CYP with T1DM and the individuals caring for them.

6 March 2020 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
BKBarbara Kimbell
Barbara Kimbell
DRDavid Rankin
David Rankin
NANicole L. Ashcroft
Nicole L. Ashcroft
LVLidiya Varghese
Lidiya Varghese
JAJanet M. Allen
Janet M. Allen
JLJulia Lawton
Julia Lawton
Background: We explored health professionals' views about the training, support, and resourcing needed to support people using closed-loop technology in routine clinical care to help inform the development of formal guidance. Methods: Interviews were conducted with health professionals ( n = 22) delivering the Closed Loop from Onset in Type 1 Diabetes (CLOuD) trial after they had ≥6 months' experience of supporting participants using a closed-loop system. Data were analyzed descriptively. Results: Interviewees described how, compared with other insulin regimens, teaching and supporting individuals to use a closed-loop system could be initially more time-consuming. However, they also noted that after an initial adjustment period, users had less need for initiating contact with the clinical team compared with people using pumps or multiple daily injections. Interviewees highlighted how a lessened need for ad hoc clinical input could result in new challenges; specifically, they had fewer opportunities to reinforce users' diabetes knowledge and skills and detect potential psychosocial problems. They also observed heightened anxiety among some parents due to the constant availability of data and unrealistic expectations about the system's capabilities. Interviewees noted that all local diabetes teams should be empowered to deliver closed-loop system care, but stressed that health professionals supporting closed-loop users in routine care will need comprehensive technology training and standardized clinical guidance. Conclusion: These findings constitute an important starting point for the development of formal guidance to support the rollout of closed-loop technology. Our recommendations, if actioned, will help limit the potential additional burden of introducing closed-loop systems in routine clinical care and help inform appropriate user education and support.